secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001828185-24-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo
--------------------------------------------------------------------------------

- HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.
- IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.
- 84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.
- All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.
- Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/0001828185-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000063/brns-20240606.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer